A nasal spray that forms a barrier against COVID-19 is due to be launched locally next week, providing a secondary layer of protection, particularly in crowded, enclosed and high-risk settings.
Touted as an additional, clinically-proven tool in the battle against the coronavirus, the Israeli product, Taffix™ (Powder) Spray Device, claims to offer 97 per cent shielding from respiratory viruses in the nasal cavity – also blocking SARS-CoV-2.
Every application works within 50 seconds and gives five-hour protection, the manufacturer, Nasus Pharma said.
It insists, however, that intra-nasal antiviral protection does not replace the wearing of face masks. The company strongly recommends it is used in addition to other preventative health measures, including social distancing, regular hand washing and compliance with other government restrictions.